HF
SLXN

HRT Financial’s Silexion Therapeutics SLXN Stock Holding History

HRT Financial’s Portfolio SLXN Stock Details SLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-79
Closed -$23K – 3559
2024
Q4 		$23K Buy
79
+12
+18% +$5.09K ﹤0.01% 2190
2024
Q3 		$47K Buy
+67
New +$105K ﹤0.01% 2117

Other funds holding SLXN

WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MHC
Meyer Handelman Company Rye Brook, New York $3.22B AUM 24.51% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

HRT Financial's SLXN Position: Q1 2025 in Review

HRT Financial sold out of Silexion Therapeutics (SLXN) in Q1 2025, closing a stake of 79 shares — an estimated $23K sold.

HRT Financial first reported a position in SLXN in Q3 2024 and held it in 2 quarters. The position peaked at $47K in Q3 2024. 5 funds tracked by Wall St. Rank hold SLXN as of Q1 2025.

  • HRT Financial reported no remaining Silexion Therapeutics position as of Q1 2025 after selling out during the quarter.
  • HRT Financial sold 79 Silexion Therapeutics shares in Q1 2025, an estimated $23K.
  • HRT Financial first reported a position in Silexion Therapeutics in Q3 2024 and held it in 2 quarters.
  • HRT Financial's Silexion Therapeutics position peaked at $47K in Q3 2024.
  • 5 funds tracked by Wall St. Rank held Silexion Therapeutics as of Q1 2025.

Based on HRT Financial's 13F filing for Q1 2025, filed 15 May 2025.